Company Description

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.

The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.

Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Pharvaris N.V.

Country	Switzerland
Founded	2015
IPO Date	Feb 5, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	134
CEO	Berndt Axel Modig

Contact Details

Address: Grafenauweg 8 Zug, 6300 Switzerland
Phone	31 712036410
Website	pharvaris.com

Stock Details

Ticker Symbol	PHVS
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	EUR
IPO Price	$20.00
CIK Code	1830487
CUSIP Number	N6954L107
ISIN Number	NL00150005Y4
SIC Code	2834

Key Executives

Name	Position
Berndt Axel Edvard Modig CPA, M.B.A.	Co-Founder, Chief Executive Officer and Executive Director
Dr. Anne A. Lesage Ph.D.	Chief Early Development Officer
Wim Souverijns Ph.D.	Chief Commercial Officer
Maryann Cimino	Director of Corporate Relations

Latest SEC Filings

Date	Type	Title
Jun 29, 2026	144	Filing
Jun 29, 2026	144	Filing
Jun 29, 2026	144	Filing
Jun 26, 2026	144	Filing
Jun 26, 2026	6-K	Report of foreign issuer
Jun 25, 2026	144	Filing
Jun 25, 2026	144	Filing
Jun 25, 2026	144	Filing
Jun 25, 2026	144	Filing
Jun 18, 2026	144	Filing

View All SEC Filings